Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Exagen Q2 Adj. EPS $(0.18) Misses $(0.14) Estimate, Sales $17.202M Beat $16.233M Estimate

Author: Benzinga Newsdesk | July 29, 2025 08:06am
Exagen (NASDAQ:XGN) reported quarterly losses of $(0.18) per share which missed the analyst consensus estimate of $(0.14) by 28.57 percent. This is a 12.5 percent decrease over losses of $(0.16) per share from the same period last year. The company reported quarterly sales of $17.202 million which beat the analyst consensus estimate of $16.233 million by 5.97 percent. This is a 14.19 percent increase over sales of $15.064 million the same period last year.

Posted In: XGN


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist